RxDoctor Payments Data

Ashley Fuller, MD

Obstetrics & Gynecology · Seattle, WANPI 1912100116

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $47,583 of the $57,001 with a category attached, or 83.5%. Astellas Pharma US Inc accounts for 96.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $31,888 and has fallen 94.5% since, to $1,768 in 2025. Among obstetrics & gynecology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$57,001in general payments, 2019–2025

Across 74 payments — averaging $770.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$55K
  • Scynexis, Inc.$1K
  • Cosette Pharmaceuticals Inc.$177
  • Sumitomo Pharma America, Inc.$108
  • AbbVie$94
  • Agile Therapeutics, Inc.$65
  • plus $158 from 5 others
$7,797,095in research payments, 2019–2025

Across 337 payments — averaging $23,137 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$6.7M
  • Mylan Inc.$401K
  • Organon$377K
  • Teva Pharmaceuticals USA, Inc.$117K
  • GSK$98K
  • Pfizer$68K
  • plus $61K from 1 others

What the payments were for

  • Speaking & faculty fees$47,58383%
  • Travel & lodging$6,80512%
  • Food & beverage$2,6135%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,001 in reported general payments places this provider in the 95th percentile of 733 obstetrics & gynecology providers in Washington.

See all obstetrics & gynecology providers in Washington

Medicare billing

Part B allowed, 2024
$7,488
Medicare patients
43
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImvexxyEstradiol18$9,343
Estradiol91$8,379
EstringEstradiol15$8,232
Estradiol (Twice Weekly)Estradiol27$4,400
ProgesteroneProgesterone, Micronized54$2,292
ValacyclovirValacyclovir Hcl22$1,204
Clobetasol Propionate25$847

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →